# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001558370-23-002102
Filing Date
2023-02-27
Accepted
2023-02-27 06:45:56
Documents
88
Period of Report
2022-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | plx-20221231x10k.htm iXBRL | 10-K | 2228318
2 | EX-4.7 | plx-20221231xex4d7.htm | EX-4.7 | 18290
3 | EX-23.1 | plx-20221231xex23d1.htm | EX-23.1 | 7636
4 | EX-31.1 | plx-20221231xex31d1.htm | EX-31.1 | 11428
5 | EX-31.2 | plx-20221231xex31d2.htm | EX-31.2 | 11090
6 | EX-32.1 | plx-20221231xex32d1.htm | EX-32.1 | 5658
7 | EX-32.2 | plx-20221231xex32d2.htm | EX-32.2 | 5565
8 | GRAPHIC | plx-20221231x10k001.jpg | GRAPHIC | 30224
9 | GRAPHIC | plx-20221231x10k002.jpg | GRAPHIC | 56468
10 | GRAPHIC | plx-20221231x10k003.jpg | GRAPHIC | 62379
11 | GRAPHIC | plx-20221231x10k005.jpg | GRAPHIC | 3480
12 | GRAPHIC | plx-20221231xex23d1001.jpg | GRAPHIC | 4679
| Complete submission text file | 0001558370-23-002102.txt |  | 8669084

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
13 | EX-101.SCH | plx-20221231.xsd | EX-101.SCH | 60870
14 | EX-101.CAL | plx-20221231_cal.xml | EX-101.CAL | 55273
15 | EX-101.DEF | plx-20221231_def.xml | EX-101.DEF | 258800
16 | EX-101.LAB | plx-20221231_lab.xml | EX-101.LAB | 427734
17 | EX-101.PRE | plx-20221231_pre.xml | EX-101.PRE | 420983
82 | EXTRACTED XBRL INSTANCE DOCUMENT | plx-20221231x10k_htm.xml | XML | 1233008

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-33357 | Film No.: 23669985
SIC: 2836 Biological Products, (No Diagnostic Substances)